Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

This trial is testing a combination of two drugs — enasidenib (a targeted therapy) and azacitidine (a chemotherapy drug) — in patients with acute myeloid leukemia (AML, a fast-growing blood cancer) whose cancer has a specific gene change called an IDH2 mutation and whose cancer has come back or stopped responding to treatment. **You may be eligible if...** - You have been diagnosed with AML or a related blood cancer that has an IDH2 gene mutation - Your cancer has failed prior treatment, or you are newly diagnosed and over 60 years old and cannot tolerate intensive chemotherapy - You are well enough to carry out some daily activities (performance status 0–3) - Your kidney and liver functions are within acceptable ranges **You may NOT be eligible if...** - Your AML does NOT have an IDH2 mutation - You have been previously treated with enasidenib - You are pregnant or breastfeeding - You have certain serious conditions like uncontrolled infection or severe organ dysfunction - You have active or untreated cancer of the brain or spinal fluid Talk to your doctor to see if this trial is right for you.